Hls Therapeutics — Q3 2021 Earnings Presentation

5 slides from Hls Therapeutics's earnings presentation, Nov 4, 2021

Slide 1: Q3 2021 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q3 2021 Results Conference Call November 4, 2021 TSX - HLS
Slide 2: Forward-looking statements
Forward-looking statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Salesforce expansion: Pfizer co-promotion partner
Salesforce expansion: Pfizer co-promotion partner Physician Validation of Coverage with Vascepa Salesforce Expansion from a well-respected partner with a strong reputation and Initial Physician commitment to the Coverage CV space >3x increase in sales reps and >4x increase in coverage Provided Novem
Slide 4: Vascepa: prescription momentum growing
Vascepa: prescription momentum growing… Weekly script data since launch …fueled by growth catalysts 700 600 Private market access • >90% eligible for coverage 500 Inclusion in Canadian medical Prescriptions 400 society guidelines • Canadian Cardiovascular Society, Heart & Stroke, Thrombosis Canada 3
Slide 5: Q3 2021 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q3 2021 Results Conference Call November 4, 2021 TSX - HLS